Multiple catalysts ahead for Cadila Healthcare: HDFC Securities

Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.

Cadila Healthcare posts consolidated PAT of Rs. 679 Cr

Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21

Cadila Healthcare divests animal health business: ICICI Securities

The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.

Investment opportunities in India’s healthcare sector: NITI Aayog

Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector

Cadila Healthcare Q3FY21 consolidated PAT up at Rs. 527.2 Cr

The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA

Moderna discontinues congenital virus program after Phase 3 trial fails to meet primary endpoint

Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years

Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits